The Italian Consultancy Group, with over 45 global branches, invests in artificial intelligence: establishing a new department and a strategic partnership for a cutting-edge and responsible future

PQE Group, a leading consultancy in the Life Science sector, announces the consolidation of its new Regulated Artificial Intelligence & Data Analytics division operating since the initiation of AI based tools in the industrial space. This marks a pivotal step in the company's evolution, positioning the Italian Group, comprised of more than 2000 employees, at the forefront of technological innovation in Life Sciences. The new division is designed to enhance business process efficiency and effectiveness while ensuring regulatory compliance. Leveraging advanced technologies, PQE Group offers services like AI-driven decision optimization, risk reduction, and accelerated innovation, all adhering to industry regulations. The 2024 Stanford Report on AI highlighted AI's significant role in accelerating scientific discovery in 2022, with further strengthening in 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625598895/en/

Danilo Neri - Partner & Vice President Executive at PQE Group (Photo: PQE Group)

“Regulators have started addressing the expectations for these solutions, but there is still much to do, since regulated companies need detailed guidance on documentation required to ensure explainability and performance of each tool," emphasized Danilo Neri, Partner & Vice President Executive of PQE Group. "Just a few weeks ago, the final approval of the AI Act in the European Union was granted, representing the world's most advanced regulation on artificial intelligence, requiring documentation to address explainability. It is an important step, but it is equally important that penalties are effectively applied to offenders to not compromise consumer, worker, and citizen protection at the expense of innovation and market competitiveness. The full establishment of this division will allow us to consolidate our position as a leader in the sector, offering exceptional compliance approaches and tailor-made solutions to our clients that meet regulatory expectations and the increasingly complex market needs." PQE Group’s dedicated validation approach has been designed to meet the current regulatory expectations for machine learning-based tools and for Generative AI solutions.

PQE Group's partnership with the Canadian company GenAIz will further boost service capacity. GenAIz, focused on the use of AI for supporting humanity, has developed a platform to speed up decision-making and execution with better business insights. This collaboration will enhance PQE Group's ability to offer innovative solutions and the necessary validation packages required by GxP regulations and by incoming industry wide rules (e.g., European AI act). Led by Catherine Lunardi, CEO of GenAIz and a spokesperson at the G7 on AI and wellbeing, GenAIz's AI platform will leverage PQE Group's global presence, which includes more than 45 offices worldwide.

The Regulated Artificial Intelligence & Data Analytics division will be presented in a panel discussion and networking event in Rockville, MD, on July 17, 2024. Experts will discuss AI regulations and the future of life sciences, marking a significant innovation for the pharmaceutical and medical device industry.

The press and readers are warmly invited to the event.

Please confirm attendance and find more information by registering here: https://hubs.ly/Q02CMQrj0

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625598895/en/

PQE Group Press Office

Michela Lijoi

press@pqegroup.com
m.lijoi@pqegroup.com

Tel: +39 328 6353044

Logo

Images

Tags

More Like This

PQE Group Reports Solid Year-End Results, Strengthens Position through Innovation in Pharmaceuticals and Medical Devices

PQE Group: 100+M€ in Revenues

ETQ Launches AI-Based Predictive Quality Analytics Solution

European Enterprises Accelerate Responsible AI Adoption

Quantexa Unleashes Wave of Next-Gen AI Decision Intelligence at QuanCon25

Enterprises in Europe Leveraging Cognitive AI for Data Insights, ISG Study Finds

Sofinnova Partners Unveils Sofinnova.AI: A Cutting-edge Artificial Intelligence Platform Set to Transform Its Life Sciences Investment Practice

Elsevier supports Pistoia Alliance in accelerating safe and responsible AI adoption in drug discovery